Journal of hepatology
Audio Summaries

A Multi-Analyte cfDNA-based Blood Test for Early Detection of Hepatocellular Carcinoma

May 8, 2026

The authors aimed to evaluate the performance of the HelioLiver Dx blood test for the early detection of hepatocellular carcinoma (HCC) in high-risk patients with cirrhosis, comparing its sensitivity and specificity to that of abdominal ultrasound. In a multicenter validation study involving 1,268 participants, the HelioLiver Dx test demonstrated superior sensitivity for detecting HCC lesions, particularly small ones, while maintaining non-inferior specificity compared to ultrasound. This study highlights the potential of a more accessible blood-based test to enhance early HCC detection and improve clinical outcomes for at-risk populations.

CD34⁺ cell-Derived Endothelial Cells Orchestrate Vascular and Immune Remodeling in the Transplanted Liver

May 4, 2026

The authors investigate the origin and role of CD34⁺ cell-derived endothelial cells (ECs) in acute cellular rejection following liver transplantation. They reveal that these recipient-derived ECs exacerbate rejection by activating T cells through the CXCL12-CXCR4 axis and propose a platelet-based delivery system targeting CXCL12 to mitigate this immune response. This study highlights the dual origin of ECs in transplanted livers and offers insights into potential immunosuppressive strategies.

Harnessing the oral microbiome in chronic liver disease: mechanisms, therapeutic modulation and translational frontiers

May 1, 2026

The authors investigate the role of the oral microbiome in advanced chronic liver disease (ACLD) and its implications for systemic inflammation and hepatic complications. They aim to highlight the mechanisms linking oral dysbiosis to liver injury and propose both immediate clinical practices and innovative therapeutic strategies to improve patient outcomes. The review seeks to synthesize current knowledge and identify gaps in understanding the oral-gut-liver axis, ultimately advocating for the integration of oral health into hepatology care.

Uncovering immune dysfunction in ACLF: cellular mechanisms, molecular pathways, and therapeutic frontiers

May 1, 2026

This review investigates the cellular and molecular mechanisms responsible for immune dysfunction in acute-on-chronic liver failure (ACLF), aiming to clarify how these alterations contribute to excessive inflammation and increased susceptibility to infections and multi-organ failure. The authors discuss various immune alterations, including innate and adaptive immune dysfunction, and explore the underlying molecular pathways that drive these changes, ultimately highlighting potential biomarkers and therapeutic strategies to restore immune balance in ACLF patients.

Tim-3 facilitates dendritic cell ferroptosis and impairs anti-tumor immunity in steatohepatitis-related HCC

Apr 26, 2026

The authors investigate how the lipid-rich microenvironment in metabolic dysfunction-associated steatotic liver disease (MASLD) contributes to immune suppression and resistance to immunotherapy in hepatocellular carcinoma (HCC). They identify Tim-3 as a key regulator of dendritic cell (DC) ferroptosis, which impairs CD8⁺ T cell activation and promotes tumor progression. The study suggests that targeting Tim-3 may enhance anti-tumor immunity and improve treatment outcomes in patients with steatohepatitic HCC.

Single-nucleus profiling reveals hepatocyte identity and immune features associated with corticosteroid response in severe alcohol-related hepatitis

Apr 22, 2026

The authors aimed to investigate the cellular changes associated with corticosteroid response in severe alcohol-related hepatitis (sAH) and identify baseline markers predictive of treatment outcomes. Through single-nucleus RNA sequencing of liver biopsies, they found that corticosteroid responders exhibited distinct immune profiles and maintained higher levels of mature hepatocyte identity compared to non-responders. Notably, the expression of SULT2A1 was identified as a strong predictor of corticosteroid response, suggesting its potential use in stratifying treatment approaches for sAH patients.

Vitamin B6 predicts poor outcomes in geographically distinct populations with primary sclerosing cholangitis

Apr 19, 2026

The authors aimed to validate the association between vitamin B6 deficiency and poor outcomes in primary sclerosing cholangitis (PSC) across geographically distinct populations, specifically in U.S. and German cohorts. Their findings confirmed that low levels of vitamin B6 were prevalent and consistently linked to reduced liver transplantation-free survival and increased incidence of hepatic decompensation, highlighting the importance of monitoring and addressing vitamin B6 deficiency in PSC patients.

Fusobacterium nucleatum alleviates alcohol-associated liver disease through mannose-mediated elevation of Fbp1 and modulation of gut microbiota

Apr 19, 2026

The authors investigate the role of Fusobacterium nucleatum in alleviating alcohol-associated liver disease (ALD) and its underlying mechanisms. They find that F. nucleatum enhances the hepatic gluconeogenic enzyme Fbp1 through mannose, which helps mitigate liver injury and modulates gut microbiota. This study suggests that targeting microbiota-derived metabolites like mannose could be a promising therapeutic strategy for ALD.

144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trial

Apr 12, 2026

This study investigates the long-term efficacy and safety of bulevirtide monotherapy for chronic hepatitis D (CHD) over 144 weeks, including outcomes after treatment discontinuation. The results indicate that while response rates decreased post-treatment, a subset of patients maintained undetectable hepatitis D virus (HDV) RNA, with the duration of undetectability at the end of treatment being a key predictor of sustained response. The findings suggest that while most patients benefit from continued treatment, some may safely discontinue without losing their therapeutic gains.

Chromatin remodeling in pericentral hepatocytes modulates MASH through CYP450 activity

Apr 5, 2026

The authors investigate how DPF2, a chromatin remodeling factor in Lgr5⁺ hepatocytes, regulates hepatic metabolism and contributes to the progression of metabolic liver diseases like MASLD and MASH. They demonstrate that loss of DPF2 leads to increased CYP2 enzyme activity, excessive metabolism of all-trans retinoic acid (atRA), and reduced AMPK phosphorylation, ultimately disrupting liver metabolic homeostasis. Their findings suggest that maintaining atRA levels could be a potential therapeutic strategy for managing these liver diseases.